Standard of treatment of depression
A course of psychotherapy and the use of anti-depressants. In most cases, such therapy is effective, but not always it acts as quickly as we would like. Researchers have proposed a method that can accelerate the improvement of patients’ condition.
The solution can be a nasal spray with Esketamine (Esketamine, also known as-ketamine or S-ketamine and sold under the brand names Ketanest and Ketanest S among others, is a general anesthetic and a dissociative hallucinogen), a derivative of a strong analgesic and dissociative substance of ketamine. It helps to cope with depression much more quickly and can be recommended for patients with clinical depression who are addicted to suicide. Esketamine is devoid of certain characteristics of ketamine – so, it does not have hallucinogenic properties, which makes it safer.
Carla Canuso and her colleagues conducted a double-blind study that tested the effectiveness of nasal spray with Escetamine to treat depression. A total of 68 patients took part in the study, which was divided into two groups: one received a placebo and the other received an experimental drug.
The experiment lasted 4 weeks – participants received drugs twice a day. In addition, each of them passed its standard, previously prescribed, treatment of depression.
The effect of Eescetamine was evaluated after 4 hours, 24 hours and 25 days after first use. Compared with those who were included in the placebo group, the experimental group experienced improvements already in the first day after admission, after 4 hours there was a difference. The results achieved 25 days after the start of the experiment were comparable in both groups. Patients experienced side effects associated with taking medications – they were pretty standard – nausea, headaches, dizziness.
The authors believe that a nasal spray with Eescetamine may be a really suitable remedy for patients with clinical depression who have suicidal tendencies. It acts very quickly and gives relief, while the effect of taking antidepressants appears only after 4-6 weeks.
In their further research, the scientists plan to study the possible risks associated with taking escetamine, and then proceed to phase III clinical trials.